BriaCell Therapeutics Corp. (BCTX) Interest & Investment Income (2021 - 2026)

BriaCell Therapeutics has reported Interest & Investment Income for 6 years, with the latest figure at $219220.0 in Q2 2026.

• Quarterly Interest & Investment Income rose 723.15% year-over-year to $219220.0 in Q2 2026, while the trailing twelve-month figure through Apr 2026 was $406784.0 (up 370.18% YoY) and the FY2025 annual result came in at $119958.0, down 58.35% from the prior year.
• Interest & Investment Income climbed to $219220.0 in Q2 2026 per BCTX's latest filing, from $105638.0 in the prior quarter.
• Over five years, Interest & Investment Income peaked at $253489.0 in Q2 2023 and troughed at $2.0 in Q3 2024.
• A 5-year average of $100164.2 and a median of $65038.5 in 2024 frame the typical range for Interest & Investment Income.
• The sharpest annual moves came in 2024 and 2025: Interest & Investment Income sank 100.0% in 2024, then surged 1672100.0% in 2025.
• Over 5 years, Interest & Investment Income stood at $188353.0 in 2022, then gained by 1.31% to $190815.0 in 2023, then tumbled by 93.16% to $13050.0 in 2024, then surged by 271.51% to $48482.0 in 2025, then soared by 352.17% to $219220.0 in 2026.
• According to Business Quant data, Interest & Investment Income over the past three periods registered $219220.0, $105638.0, and $48482.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.